πŸ‡ΊπŸ‡Έ FDA
Patent

US 11185575

Subcutaneous administration of ADAMTS13

granted A61KA61K38/4886A61K9/0019

Quick answer

US patent 11185575 (Subcutaneous administration of ADAMTS13) held by Takeda Pharmaceutical Company Limited expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K38/4886, A61K9/0019, A61K9/19, A61P